• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: BIO-TECHNOLOGY GENERAL (ISRAEL) LTD. EUFLEXXA; 1% SODIUM HYALURONATE

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

BIO-TECHNOLOGY GENERAL (ISRAEL) LTD. EUFLEXXA; 1% SODIUM HYALURONATE Back to Search Results
Catalog Number 6301182010
Device Problem Adverse Event Without Identified Device or Use Problem (2993)
Patient Problem Anemia (1706)
Event Date 12/20/2019
Event Type  Injury  
Event Description
Anemic [anaemia] case (b)(6) is a serious spontaneous case received from a consumer via regulatory authority in united states.This report concerns a patient (no identifiers reported) who was anemic during treatment with euflexxa (sodium hyaluronate) solution for injection 1 %, 10mg/1ml, unknown dose and frequency for an unknown indication from an unknown start date and unknown if ongoing the patient was in the hospital due to being anemic and stated that they added an antacid for 30 days but did not know the name of it.The patient had no missed dose.The patient was hospitalized on an unknown date due to anemic.Action taken with euflexxa was unknown.At the time of the report, the outcome of anemic was unknown.No concomitant medication was reported.All events in the case were reported as serious.At the time of reporting the case outcome was unknown.Overall listedness (core label) is unlisted.Reporter causality: related.Company causality: not related.Sender comment (ferring): this case contains very limited information, especially current conditions and medical history, incl.Concomitant medication which is essential information for a proper causality assessment, have not been reported.However, based on the known safety profile of euflexxa, it is considered highly unlikely that euflexxa was involved in causing the anaemia.Company causality is not related.Other case numbers: internal # - others = mw5091958 this ae occurred in united states and concerns the medical device euflexxa.Please report to your local health authority if required by local law.This ae is not reportable in eu because it did not occur in a eu + efta country and did not result in a corrective action by the manufacturer.No corrective action was done by the manufacturer or requested by regulators.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
EUFLEXXA
Type of Device
1% SODIUM HYALURONATE
Manufacturer (Section D)
BIO-TECHNOLOGY GENERAL (ISRAEL) LTD.
be'er tuvia industrial zone
pob 571
kiryat malachi, 83104
IS  83104
Manufacturer (Section G)
BIO-TECHNOLOGY GENERAL (ISRAEL) LTD.
be'er tuvia industrial zone
pob 571
kiryat malachi, 83104
IS   83104
Manufacturer Contact
100 interpace parkway
parsippany, nj 
3044828
MDR Report Key9694403
MDR Text Key178599001
Report Number3000164186-2020-00003
Device Sequence Number1
Product Code MOZ
Combination Product (y/n)N
Reporter Country CodeUS
PMA/PMN Number
P010029
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type consumer
Reporter Occupation Other
Type of Report Initial
Report Date 01/29/2020
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator No Information
Device Catalogue Number6301182010
Was Device Available for Evaluation? No
Initial Date Manufacturer Received 01/14/2020
Initial Date FDA Received02/11/2020
Is the Device Single Use? Yes
Type of Device Usage N
Patient Sequence Number1
Patient Outcome(s) Hospitalization;
-
-